Lenvatinib-associated hyaline occlusive glomerular microangiopathy
Abstract
ABSTRACT Nephrologists play a key role in managing renal complications related to malignancy and its treatment. Although immunotherapies and oral small-molecule agents have revolutionized cancer care, severe adverse events may limit their use. We report a distinctive glomerular injury pattern associated with lenvatinib, an oral receptor tyrosine kinase inhibitor. Similar histopathologic features have been observed with bevacizumab and antivascular endothelial growth factor receptor 2 (VEGFR2) antibodies. This case includes extended clinical follow-up, kidney biopsy findings, and therapeutic modification, suggesting a possible association between VEGF–VEGFR2 pathway inhibition and reversible nephrotoxicity.
Fields of Study & Subjects
Renal cell carcinoma treatment
Renal Diseases and Glomerulopathies
Chemotherapy-induced organ toxicity mitigation
Publication details
- Journal / source
- Clinical Kidney Journal
- Publisher
- Oxford University Press (OUP)
- Volume
- 19
- Issue
- 4
- Publication date
- 19 March 2026
- Language
- EN